Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04543110
Recruitment Status : Recruiting
First Posted : September 9, 2020
Last Update Posted : June 15, 2021
Sponsor:
Collaborators:
Cross Cancer Institute
Hamilton Health Sciences Corporation
London Health Sciences Centre
Ontario Institute for Cancer Research
AstraZeneca
Ozmosis Research Inc.
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.

Condition or disease Intervention/treatment Phase
Bladder Cancer Drug: Durvalumab Radiation: Immune Modulating Radiation Phase 2

Detailed Description:
In this phase II study, patients who are either not eligible or declined to have chemotherapy prior to surgery for muscle-invasive bladder cancer may consent and enrol to study. Patients will have single 8 Gy hypofractionated radiation to bladder followed by 3 cycles of durvalumab immunotherapy prior to radical cystectomy. This study will assess the safety and tolerability, pathological and radiological response, and immune biological correlatives to understand the effect of radiation and durvalumab.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Safety run-in of 6 patients, followed by two-stage Fleming phase II design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neoadjuvant Immune-Modulating Radiation With Durvalumab (MEDI4736) Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)
Actual Study Start Date : January 29, 2021
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : November 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer
Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Single Arm
Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
Drug: Durvalumab
Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
Other Name: (MEDI4736)

Radiation: Immune Modulating Radiation
Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
Other Name: Neoadjuvant Immune Modulating Radiation




Primary Outcome Measures :
  1. Pathological Complete Response (pCR) Rate [ Time Frame: Up to 2 years ]
    pCR rate is defined as the proportion of patients whose pathological staging was T0N0M0 as assessed using specimens obtained post radical cystectomy following the study intervention.


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Up to 2 years ]
    Adverse events related to the study treatment will be identified and characterized using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the Cancer Therapy Evaluation Program website (http://ctep.cancer.gov). Data will be collected from time of confirmed study entry

  2. Rate of delay of surgery [ Time Frame: Up to 2 years ]
    Feasibility. Surgery is expected to occur within 90 days of radiotherapy. Any delay beyond that will be noted and the cause of the delay attributed to study intervention or otherwise, with supporting details.

  3. Rate of Pathological Downstaging [ Time Frame: Up to 2 years ]
    Proportion of patients who have pathological staging <T2 as determined after radical cystectomy.

  4. Recurrence rates at 1 year and 2 years [ Time Frame: Up to 2 years ]
    he proportion of patients who have radiographically confirmed recurrence of their cancer at 1 and 2 years. Time to recurrence is defined from the time of study entry to the first recurrence of disease after cystectomy. A recurrence of disease includes local (pelvic) recurrence, urinary tract recurrence, or distant metastases of urothelial carcinoma. Recurrence rate will be assessed using computed tomography (CT)/magnetic resonance imaging (MRI) and/or Positron Emission Tomography (PET)-CT (per standard local imaging practices) and pathology testing performed according to local standards and as clinically indicated.

  5. Overall survival rate at 1 and 2 years [ Time Frame: Up to 2 years ]
    The proportion of patients who are alive at 1 and 2 years. Overall survival is defined from the date of study entry until death of any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is willing and able to provide written informed consent
  2. Patient is willing and able to comply with the protocol
  3. Age ≥ 18 years
  4. Body weight >30 kg.
  5. Histopathologically confirmed transitional cell carcinoma/urothelial carcinoma (TCC/UC).

    1. Patients with mixed transitional/non-transitional cell histologies (adenocarcinoma, squamous cell) or variant transitional histology (eg, micropapillary, plasmacytoid, sarcomatoid, nested variant, lymphoepithelioid, nested variant) are eligible.
    2. Patients with pure non-transitional cell variant histologies and/or any component of small cell histology are not eligible.
  6. Clinical stage T2-T4a N0 M0 TCC/UC, as evaluated by CT, MRI and/or PET (per standard local imaging practices) within 4 weeks prior to randomization.
  7. Fit and planned for cystectomy (according to local guidelines).
  8. Ineligible for neoadjuvant cisplatin-based chemotherapy OR patient declines to receive neoadjuvant cisplatin-based chemotherapy

    a) Ineligibility for chemotherapy include any of: i) Poor renal function (GFR < 50 ml/min) ii) Poor performance status (ECOG PS ≥ 2) iii) Significant (grade ≥2) neuropathy iv) Significant (grade ≥2) hearing loss v) Heart failure (NYHA-class-III/IV) OR b) Declining to receive neoadjuvant cisplatin regimen is documented by consultation with medical oncologist

  9. Deemed by investigator to be medically fit (at the time of enrollment) for:

    1. Radiotherapy to pelvis
    2. Immunotherapy with durvalumab
    3. Radical cystectomy
  10. Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (blocks preferred) or at least 15 unstained slides, with an associated pathology report
  11. ECOG performance status of 0-1
  12. Adequate hematologic and end-organ function tests.

    1. Hemoglobin ≥9.0 g/dL
    2. Absolute neutrophil count ≥1.5×109/L
    3. Platelet count ≥100×109/L
    4. Serum bilirubin ≤1.5×the upper limit of normal (ULN).

    i) This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed after discussion with the study sponsor / medical monitor.

    e) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0×ULN f) CrCl >40 mL/min calculated by Cockcroft-Gault equation (using actual body weight) or measured by 24-hour urine collection for determination. In cases where both are performed, measured 24- hour urine collection will be used to determine eligibility, providing an adequate collection was performed.

  13. Must have a life expectancy of at least 12 weeks at enrollment
  14. Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of at least 90 days after the last dose of durvalumab. A highly effective method of birth control (as defined in Section 8.7.2) are those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
  15. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 mIU/mL to confirm menopause.
  16. Females must not be breastfeeding at time of enrollment until at least 90 days after last dose of durvalumab
  17. Male patients should agree to not donate sperm during the study until at least 90 days after the last dose of durvalumab

Exclusion Criteria:

  1. Evidence of suspected metastatic lymph node(s) (defined as short axis measurement of ≥10 mm as per IV contrast-enhanced CT or MRI scan) and/or PET-CT scan
  2. Extravesical TCC/UC that invades the pelvic and/or abdominal wall for bladder cancer (T4b)
  3. Distantly metastatic TCC/UC
  4. Primary non-bladder (ie, ureter, urethral, or renal pelvis) TCC/UC
  5. Inoperable tumor(s) with fixation to the pelvic wall on clinical exam
  6. History of allogeneic organ transplantation that requires use of immunosuppressive agents. Patients with a history of allogenic stem cell transplantation are also excluded.
  7. Malignancies other than TCC/UC within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (Gleason score ≤ 3 + 4 and PSA < 10 ng/mL undergoing active surveillance and treatment naive).
  8. Any history of autoimmune disease or connective tissue disorder including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, glomerulonephritis, or scleroderma.

    a) The following are exceptions to this criterion: i) Patients with vitiligo or alopecia ii) Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on thyroid replacement iii) Any chronic skin condition that does not require systemic therapy iv) Patients with celiac disease controlled by diet alone may be included after consultation the study sponsor and medical monitor v) Patients without active autoimmune disease in the last 5 years may be included after consultation with the study sponsor and medical monitor

  9. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
  10. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria

    a) Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after discussion with the study sponsor / medical monitor.

  11. History of idiopathic pulmonary fibrosis
  12. History of active primary immunodeficiency
  13. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder)
  14. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 6 months prior to enrolment, unstable arrhythmias, or unstable angina.
  15. Severe infections within 4 weeks prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
  16. Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
  17. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  18. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the durvalumab formulation
  19. History of any illness or disease that would significant compromise patient ability to receive radiation or any reason that would preclude a patient from radiation therapy as delivered by this study design
  20. Prior systemic treatment for TCC/UC

    a) Prior local intravesical chemotherapy or immunotherapy (e.g. BCG) is allowed if completed at least 6 weeks prior to initiation of study treatment

  21. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer- related conditions (eg, hormone replacement therapy) is acceptable.
  22. Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies.
  23. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.

    Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.

  24. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
  25. Prior pelvic radiotherapy treatment
  26. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrolment
  27. Concurrent enrollment in another clinical study unless it is non- interventional or during the follow-up period of an interventional study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04543110


Contacts
Layout table for location contacts
Contact: Michael Ong, MD 613-737-7700 ext 70179 mong@toh.ca

Locations
Layout table for location information
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada
Contact: Naveen Basappa         
Canada, Ontario
Juravinski Cancer Centre Recruiting
Hamilton, Ontario, Canada
Contact: Aly-Khan Lalani         
London Health Sciences Centre Recruiting
London, Ontario, Canada
Contact: Ricardo Fernandes, MD         
The Ottawa Hospital Cancer Centre Recruiting
Ottawa, Ontario, Canada, K1H8L6
Contact: Caroline Proulx       caproulx@ohri.ca   
Sponsors and Collaborators
Ottawa Hospital Research Institute
Cross Cancer Institute
Hamilton Health Sciences Corporation
London Health Sciences Centre
Ontario Institute for Cancer Research
AstraZeneca
Ozmosis Research Inc.
Investigators
Layout table for investigator information
Principal Investigator: Michael Ong, MD Ottawa Hospital Research Institute
Principal Investigator: Naveen Basappa, MD Cross Cancer Institute
Layout table for additonal information
Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT04543110    
Other Study ID Numbers: OTT-19-07/OZM-105
First Posted: September 9, 2020    Key Record Dates
Last Update Posted: June 15, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Qualified researchers can contact Dr. Michael Ong regarding sharing of data and be evaluated for what their purpose and plan is for the data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Ottawa Hospital Research Institute:
Urothelial Carcinoma
Muscle-Invasive Bladder Cancer
Neoadjuvant
Radiation
Durvalumab
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents